News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Genmab A/S Announces Results From Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients
March 8, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, Denmark, March 8, 2010 (GLOBE NEWSWIRE) -- Summary: Genmab announces top-line results from a study of zalutumumab in refractory head and neck cancer patients who failed platinum-based chemotherapy.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
July 14, 2025
·
1 min read
·
Dan Samorodnitsky
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
July 14, 2025
·
2 min read
·
Tristan Manalac
Depression
After Three Strikes, Relmada Abandons Depression Drug Esmethadone
July 14, 2025
·
2 min read
·
Tristan Manalac
